TASK Channels Pharmacology: New Challenges in Drug Design

Journal of Medicinal Chemistry
2019.0

Abstract

Rational drug design targeting ion channels is an exciting and always evolving research field. New medicinal chemistry strategies are being implemented to explore the wild chemical space and unravel the molecular basis of the ion channels modulators binding mechanisms. TASK channels belong to the two-pore domain potassium channel family and are modulated by extracellular acidosis. They are extensively distributed along the cardiovascular and central nervous systems, and their expression is up- and downregulated in different cancer types, which makes them an attractive therapeutic target. However, TASK channels remain unexplored, and drugs designed to target these channels are poorly selective. Here, we review TASK channels properties and their known blockers and activators, considering the new challenges in ion channels drug design and focusing on the implementation of computational methodologies in the drug discovery process.

Knowledge Graph

Similar Paper

TASK Channels Pharmacology: New Challenges in Drug Design
Journal of Medicinal Chemistry 2019.0
Ion Channels as Therapeutic Targets: A Drug Discovery Perspective
Journal of Medicinal Chemistry 2013.0
Selective TASK-1 Inhibitor with a Defined Structure–Activity Relationship Reduces Cancer Cell Proliferation and Viability
Journal of Medicinal Chemistry 2022.0
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K<sup>+</sup>Channel 1). A Novel Therapeutic Target?
Journal of Medicinal Chemistry 2016.0
Transient Receptor Potential Melastatin 8 Channel (TRPM8) Modulation: Cool Entryway for Treating Pain and Cancer
Journal of Medicinal Chemistry 2016.0
Discovery of an Inhibitor for the TREK-1 Channel Targeting an Intermediate Transition State of Channel Gating
Journal of Medicinal Chemistry 2020.0
Review of Transient Receptor Potential Canonical (TRPC5) Channel Modulators and Diseases
Journal of Medicinal Chemistry 2019.0
Development of the First Two-Pore Domain Potassium Channel TWIK-Related K<sup>+</sup>Channel 1-Selective Agonist Possessing in Vivo Antinociceptive Activity
Journal of Medicinal Chemistry 2017.0
Discovery of Small Molecule Renal Outer Medullary Potassium (ROMK) Channel Inhibitors: A Brief History of Medicinal Chemistry Approaches To Develop Novel Diuretic Therapeutics
Journal of Medicinal Chemistry 2019.0
Design and SAR of selective T-type calcium channel antagonists containing a biaryl sulfonamide core
Bioorganic &amp; Medicinal Chemistry Letters 2008.0